“THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.: Dual Myeloid Disorder Treated with Two Drug Association” (2025) Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025023. doi:10.4084/MJHID.2025.023.